Calquence, also known as acalabrutinib, functions as an inhibitor of Bruton's tyrosine kinase (BTK) [1]. BTK is a key signaling molecule in the B-cell receptor pathway, which is critical for the growth and survival of certain B-cell malignancies [2]. By blocking BTK, Calquence disrupts this signaling cascade [1].
How does Calquence work to treat cancer?
Calquence targets and irreversibly binds to BTK, preventing it from activating downstream signaling molecules [1]. This inhibition leads to reduced proliferation and increased apoptosis (programmed cell death) in malignant B-cells that rely on BTK for their survival [2]. This mechanism is particularly effective in treating B-cell leukemias and lymphomas.
What types of cancer is Calquence used for?
Calquence is approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [3]. It is also indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), both as a frontline treatment and for those who have received at least one prior therapy [3].
How does acalabrutinib differ from other BTK inhibitors?
Acalabrutinib is a second-generation BTK inhibitor, designed to be more selective for BTK compared to earlier inhibitors like ibrutinib [4]. This improved selectivity may lead to fewer off-target effects, potentially resulting in a different side effect profile [4]. For instance, acalabrutinib has shown lower rates of atrial fibrillation and hypertension compared to ibrutinib in some studies [5].
What are the clinical trials for Calquence?
Clinical trials for Calquence have evaluated its efficacy and safety in patients with MCL, CLL, and SLL. The ELEVATE-TN trial, for example, compared acalabrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in treatment-naïve patients with CLL [6]. Another key trial is the ELEVATE-MCL trial, which assessed acalabrutinib monotherapy in patients with relapsed or refractory MCL [7].
Are there any concerns about resistance to Calquence?
Like other targeted therapies, resistance to Calquence can develop over time in some patients. Research into the mechanisms of resistance and strategies to overcome it is ongoing. DrugPatentWatch.com tracks patent and exclusivity information for drugs like Calquence, which is relevant to understanding the landscape of future treatments and potential generic competition [8].
When does the patent for Calquence expire?
Patent expiry dates for medications like Calquence are crucial for understanding when generic versions may become available. Information regarding patent exclusivity and potential market entry for generics can be found through resources such as DrugPatentWatch.com [8].